These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 24410307)

  • 61. Adverse drug reactions related to the use of fluoroquinolone antimicrobials: an analysis of spontaneous reports and fluoroquinolone consumption data from three italian regions.
    Leone R; Venegoni M; Motola D; Moretti U; Piazzetta V; Cocci A; Resi D; Mozzo F; Velo G; Burzilleri L; Montanaro N; Conforti A
    Drug Saf; 2003; 26(2):109-20. PubMed ID: 12534327
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Grepafloxacin: a review of its safety profile based on clinical trials and postmarketing surveillance.
    Lode H; Vogel F; Elies W
    Clin Ther; 1999 Jan; 21(1):61-74; discussion 1-2. PubMed ID: 10090425
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The newer fluoroquinolones.
    Bolon MK
    Infect Dis Clin North Am; 2009 Dec; 23(4):1027-51, x. PubMed ID: 19909896
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Oral fluoroquinolone use and risk of peripheral neuropathy: a pharmacoepidemiologic study.
    Etminan M; Brophy JM; Samii A
    Neurology; 2014 Sep; 83(14):1261-3. PubMed ID: 25150290
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Fluoroquinolone-induced liver injury: three new cases and a review of the literature.
    Licata A; Randazzo C; Morreale I; Butera G; D'Alessandro N; Craxì A
    Eur J Clin Pharmacol; 2012 May; 68(5):525-32. PubMed ID: 22246188
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Fluoroquinolone (FQ) contamination does not correlate with occurrence of FQ-resistant bacteria in aquatic environments of Vietnam and Thailand.
    Takasu H; Suzuki S; Reungsang A; Pham HV
    Microbes Environ; 2011; 26(2):135-43. PubMed ID: 21502737
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Photosensitized DNA damage: the case of fluoroquinolones.
    Lhiaubet-Vallet V; Bosca F; Miranda MA
    Photochem Photobiol; 2009; 85(4):861-8. PubMed ID: 19320842
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections.
    Balfour JA; Lamb HM
    Drugs; 2000 Jan; 59(1):115-39. PubMed ID: 10718103
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Treatment of the Fluoroquinolone-Associated Disability: The Pathobiochemical Implications.
    Michalak K; Sobolewska-Włodarczyk A; Włodarczyk M; Sobolewska J; Woźniak P; Sobolewski B
    Oxid Med Cell Longev; 2017; 2017():8023935. PubMed ID: 29147464
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Preserving the efficacy of front-line fluoroquinolones through selective use to optimise clinical outcomes.
    Lode HM
    Int J Antimicrob Agents; 2014 Jun; 43(6):497-507. PubMed ID: 24787481
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Fluoroquinolone treatment of community-acquired pneumonia: a meta-analysis.
    Salkind AR; Cuddy PG; Foxworth JW
    Ann Pharmacother; 2002 Dec; 36(12):1938-43. PubMed ID: 12452758
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Emergence of quinolone resistance in the microbiota of hospitalized patients treated or not with a fluoroquinolone.
    de Lastours V; Chau F; Roy C; Larroque B; Fantin B
    J Antimicrob Chemother; 2014 Dec; 69(12):3393-400. PubMed ID: 25063781
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Antibacterial activity and mechanism of action of a novel anilinouracil-fluoroquinolone hybrid compound.
    Butler MM; Lamarr WA; Foster KA; Barnes MH; Skow DJ; Lyden PT; Kustigian LM; Zhi C; Brown NC; Wright GE; Bowlin TL
    Antimicrob Agents Chemother; 2007 Jan; 51(1):119-27. PubMed ID: 17074800
    [TBL] [Abstract][Full Text] [Related]  

  • 74. What tendon pathology is seen on imaging in people who have taken fluoroquinolones? A systematic review.
    Lang TR; Cook J; Rio E; Gaida JE
    Fundam Clin Pharmacol; 2017 Feb; 31(1):4-16. PubMed ID: 27477928
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies.
    Ball P; Stahlmann R; Kubin R; Choudhri S; Owens R
    Clin Ther; 2004 Jul; 26(7):940-50. PubMed ID: 15336463
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Fluoroquinolones, the cornerstone of treatment of drug-resistant tuberculosis: a pharmacokinetic and pharmacodynamic approach.
    Pranger AD; Alffenaar JW; Aarnoutse RE
    Curr Pharm Des; 2011; 17(27):2900-30. PubMed ID: 21834759
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Gatifloxacin: a review of its use in the management of bacterial infections.
    Perry CM; Ormrod D; Hurst M; Onrust SV
    Drugs; 2002; 62(1):169-207. PubMed ID: 11790160
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Fluoroquinolones: With great power comes great risk.
    Kidd T; Mitchell S; Dehays J; Wibberley E
    Nursing; 2022 Jan; 52(1):24-27. PubMed ID: 34879046
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Oxidative transformation of fluoroquinolone antibacterial agents and structurally related amines by manganese oxide.
    Zhang H; Huang CH
    Environ Sci Technol; 2005 Jun; 39(12):4474-83. PubMed ID: 16047783
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Toxicity of quinolones.
    Stahlmann R; Lode H
    Drugs; 1999; 58 Suppl 2():37-42. PubMed ID: 10553703
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.